D. E. Shaw & Co., Inc. Acelrx Pharmaceuticals Inc Transaction History

D. E. Shaw & Co., Inc.

  • $107 Billion
  • Q3 2024

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$0.18 - $0.29 $550,873 - $887,518
-3,060,410 Reduced 80.35%
748,583 $183,000
Q1 2022

May 16, 2022
BUY
$0.28 - $0.61 $24,473 - $53,318
87,407 Added 2.35%
3,808,993 $1.09 Million
Q4 2021

Feb 14, 2022
BUY
$0.49 - $1.02 $199,678 - $415,657
407,507 Added 12.3%
3,721,586 $2.09 Million
Q3 2021

Nov 15, 2021
SELL
$0.93 - $1.51 $1.35 Million - $2.2 Million
-1,454,445 Reduced 30.5%
3,314,079 $3.38 Million
Q2 2021

Aug 16, 2021
SELL
$1.03 - $1.7 $494,765 - $816,603
-480,355 Reduced 9.15%
4,768,524 $6.58 Million
Q1 2021

May 17, 2021
BUY
$1.25 - $2.77 $5.43 Million - $12 Million
4,343,613 Added 479.82%
5,248,879 $8.92 Million
Q4 2020

Feb 16, 2021
BUY
$1.18 - $1.98 $92,469 - $155,160
78,364 Added 9.48%
905,266 $1.12 Million
Q3 2020

Nov 16, 2020
SELL
$1.01 - $1.81 $206,987 - $370,937
-204,938 Reduced 19.86%
826,902 $1.17 Million
Q2 2020

Aug 14, 2020
BUY
$1.03 - $1.69 $300,858 - $493,642
292,096 Added 39.49%
1,031,840 $1.25 Million
Q1 2020

May 15, 2020
BUY
$0.76 - $2.07 $202,736 - $552,191
266,759 Added 56.4%
739,744 $873,000
Q4 2019

Feb 14, 2020
SELL
$1.66 - $2.4 $679,207 - $981,986
-409,161 Reduced 46.38%
472,985 $998,000
Q3 2019

Nov 14, 2019
BUY
$2.1 - $2.87 $46,567 - $63,642
22,175 Added 2.58%
882,146 $1.94 Million
Q2 2019

Aug 14, 2019
BUY
$2.1 - $3.93 $1.2 Million - $2.25 Million
573,139 Added 199.82%
859,971 $2.18 Million
Q1 2019

May 15, 2019
BUY
$2.35 - $3.83 $537,014 - $875,220
228,517 Added 391.87%
286,832 $999,000
Q4 2018

Feb 14, 2019
SELL
$2.13 - $4.8 $260,121 - $586,190
-122,123 Reduced 67.68%
58,315 $135,000
Q3 2018

Nov 14, 2018
SELL
$2.6 - $4.6 $180,840 - $319,948
-69,554 Reduced 27.82%
180,438 $695,000
Q2 2018

Aug 14, 2018
BUY
$2.13 - $4.2 $187,802 - $370,314
88,170 Added 54.49%
249,992 $844,000
Q1 2018

May 15, 2018
BUY
$1.7 - $2.35 $164,966 - $228,041
97,039 Added 149.79%
161,822 $340,000
Q4 2017

Feb 14, 2018
SELL
$1.75 - $5.5 $9,009 - $28,314
-5,148 Reduced 7.36%
64,783 $131,000
Q3 2017

Nov 14, 2017
BUY
$2.9 - $4.6 $202,799 - $321,682
69,931
69,931 $322,000

About ACELRX PHARMACEUTICALS INC

ACRX Quotes by TradingView
  • Ticker ACRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 7,366,600
  • Market Cap $8.32M
  • Description
  • AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...
More about ACRX
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email